Production approval for Iclusig 45mg

Release date: 2024-07-10 11:40:26     Recommended: 340

Iclusig is used to treat certain specific stages of leukemia, but is not suitable and not recommended for the treatment of newly diagnosed chronic myeloid leukemia patients. It belongs to tyrosine kinase inhibitors, which inhibit abnormal tyrosine kinase activity in leukemia cells, blocking the proliferation and survival of leukemia cells. Iclusig is suitable for the treatment of chronic myeloid leukemia and Ph+acute lymphoblastic leukemia, especially for patients who are tolerant or intolerant to other therapeutic drugs.